Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

DOTAREM - Health Canada Drug Approval Details

Approvals/Health Canada/DOTAREM

Authorized

STANDARD

DOTAREM

LIEBEL-FLARSHEIM COMPANY LLC🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 822d0207ebc66fa3
Company: LIEBEL-FLARSHEIM COMPANY LLC
Type: Standard

Approval Details

Approval Id: 822d0207ebc66fa3
Drug Approval Canada Name: DOTAREM
Product Name: DOTAREM
Status: Marketed
Status Date: 2017-09-22
Original Market Date: 2017-09-22
Din: 02459329
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Intravenous
Schedule: Ethical
Ahfs: 36:89.00*
Atc Original: V08CA02 GADOTERIC ACID
Atc Name: v 08 ca 02
Aig Number: 0158590001
Company Name: LIEBEL-FLARSHEIM COMPANY LLC
Company Address: Bp 57400, Roissy Cdg Cedex, Val-D'Oise, France, 95943
Company Detail Path: /organization/liebel-flarsheim-company-llc

Company Information

Pharmaceutical Company Name: LIEBEL-FLARSHEIM COMPANY LLC
Country Name: United States
Province Name: Ohio
City Name: cincinnati,ohio,country_us
Address: 2111 E Galbraith Rd

Active Ingredients

GADOTERATE MEGLUMINE

376.9 MG / ML

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

822d0207ebc66fa3

Type

Standard

Back to Health Canada Approvals